{
    "clinical_study": {
        "@rank": "42078", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give efavirenz plus\n      stavudine plus didanosine to HIV-infected patients who have never received anti-HIV\n      treatment."
        }, 
        "brief_title": "A Study of Efavirenz in Combination With Stavudine and Didanosine", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be given combination treatment with efavirenz, stavudine, and didanosine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documented HIV infection with plasma HIV-RNA greater than or equal to 10,000\n             copies/ml.\n\n          -  A life expectancy of at least 12 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Current bilateral peripheral neuropathy greater than or equal to Grade 2.\n\n          -  Any clinically significant laboratory findings obtained during the screening\n             evaluation (see laboratory values).\n\n          -  Any clinically significant disease (other than HIV infection) or clinically\n             significant findings during  screening of medical history or physical examination.\n\n          -  Any malignancy that requires systemic therapy.\n\n          -  Proven or suspected acute hepatitis due to any cause.\n\n          -  Recurrent episodes of moderate to severe diarrhea, or vomiting lasting more than 4\n             days within 3 months prior to dosing.\n\n          -  Active AIDS-defining opportunistic infection or disease.\n\n        Concurrent Medication:\n\n        Excluded:\n\n        Astemizole, cisapride, clarithromycin, ketoconazole, itraconazole, midazolam, rifabutin,\n        rifampin, terfenadine, thalidomide, triazolam, vincristine, zalcitabine.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of acute or chronic pancreatitis.\n\n          -  Life expectancy less than 12 months.\n\n          -  Difficulty in swallowing capsules/tablets.\n\n          -  Hypersensitivity to any component of the formulation of efavirenz, stavudine, or\n             didanosine.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any other experimental drug within 30 days of introducing study treatment.\n\n          -  Vaccination within 3 weeks of screening visit.\n\n          -  Interferon started within 30 days of initiating study treatment.\n\n          -  Prior antiretroviral therapy.\n\n        Risk Behavior:\n\n        Excluded:\n\n        - Current alcohol or illicit drug use which would interfere with compliance with dosing\n        schedule and protocol evaluations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002225", 
            "org_study_id": "281D", 
            "secondary_id": "DMP 266-044"
        }, 
        "intervention": [
            {
                "intervention_name": "Efavirenz", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Stavudine", 
                "Reverse Transcriptase Inhibitors", 
                "Efavirenz"
            ]
        }, 
        "keyword": [
            "Didanosine", 
            "Drug Therapy, Combination", 
            "Stavudine", 
            "Reverse Transcriptase Inhibitors", 
            "efavirenz"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20009"
                    }, 
                    "name": "The Whitman Walker Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60657"
                    }, 
                    "name": "AIDS Research Alliance - Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manhassett", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11030"
                    }, 
                    "name": "North Shore AIDS Hosp / Division of Infectious Disease"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ of Rochester Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28207"
                    }, 
                    "name": "Carolinas Research Associates"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Didanosine in Antiretroviral Therapy-Naive HIV-Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002225"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dupont Merck", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "AIDS Research Alliance - Chicago": "41.878 -87.63", 
        "Carolinas Research Associates": "35.227 -80.843", 
        "North Shore AIDS Hosp / Division of Infectious Disease": "40.798 -73.7", 
        "The Whitman Walker Clinic": "38.895 -77.036", 
        "Univ of Rochester Med Ctr": "43.161 -77.611"
    }
}